AI assistant
Sending…
Insight Molecular Diagnostics Inc. — Director's Dealing 2020
Apr 30, 2020
34238_dirs_2020-04-30_404539cb-b3d4-4409-9fb1-517315d02127.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2020-04-28
Reporting Person: Levine Mitchell S (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-04-28 | Restricted Stock Units | $ | A | 20000 | Acquired | Common Stock (20000) | Direct |
Footnotes
F1: Grant of restricted stock units under the OncoCyte 2018 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Common Stock.
F2: The restricted stock units shall vest upon the completion of one year of continuous service from the date of grant.
More from Insight Molecular Diagnostics Inc.
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 17
Call Transcript
2026
May 13
Annual Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Call Transcript
2026
Apr 15
Call Transcript
2026
Mar 26
Regulatory Filings
2026
Feb 26
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Feb 12
Capital/Financing Update
2026
Feb 12